J&J: Phase 2 endpoint met in Sjögren's disease

(CercleFinance.com) - Johnson & Johnson announced on Thursday that a Phase 2 study had met its primary endpoint in the treatment of Sjögren's syndrome, an autoimmune disease characterized by dry mucous membranes.


The American pharmaceutical group reports that administration of nipocalimab, a drug still in the experimental stage, resulted in a drop of over 77% in immunoglobulin G (IgG) levels in individuals treated as part of the trial.

In addition to this 'significant' score after 24 weeks, the second endpoint was also achieved, says J&J, with a reduction in disease manifestations in several organs.

Patients reported an improvement in symptoms such as dry mouth, dry eyes and vaginal dryness, as well as less fatigue and joint pain.

Twice as many participants in the nipocalimab group (32.7%) as in the placebo group (16%) reported an improvement in saliva production.

Copyright (c) 2024 CercleFinance.com. All rights reserved.